Episurf — Investor Presentation 2016

Sep 15, 2016

Company Announcement September 15, 2016

Episurf Medical obtains its first granted patent in Australia

Episurf Medical is obtaining a granted patent in Australia. The Australian IP Office has issued a notice of allowance for the patent and has published the decision on September 15, 2016. This is the first time Episurf obtains a granted patent in Australia.

The patent covers a surgical drilling guide with a functionality for depth adjustments. This guide constitutes a component of Episurf's toolkit for implantation of patient specific joint implants.

"To look forward and secure intellectual property protection in new markets is an important field for an expanding company", comments Rosemary Cunningham Thomas, CEO of Episurf Medical.

For more information, please contact:

Rosemary Cunningham Thomas, CEO, Episurf Medical Tel: +46 (0) 70-7655892 Tel: +44 (0) 7803-753603 Email: rosemary@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10.15 CET on 15 September 2016.